-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, G17GJtYWTHpMvoUlQM9ZUmD34GIKvrqFpWcQ+HMab0+XXQfhKpCpvGxou2baspGY zBWNgdaJ6IreplO4Zd+/Ew== 0001193125-03-073372.txt : 20031105 0001193125-03-073372.hdr.sgml : 20031105 20031105153405 ACCESSION NUMBER: 0001193125-03-073372 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20031105 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20031105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 03979426 BUSINESS ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 9198621000 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 8-K 1 d8k.htm SALIX PHARMACEUTICALS, LTD Salix Pharmaceuticals, LTD

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported) November 5, 2003

 

 

SALIX PHARMACEUTICALS, LTD.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

000-23265   94-3267443
(Commission file Number)   (IRS Employer ID Number)

 

8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (919) 862-1000

 

 

 

Item 5. Other Events and Regulation FD Disclosure

 

On November 5, 2003, Salix Pharmaceuticals, Ltd. issued a press release announcing that the company will present at the CIBC World Markets Fourteenth Annual Healthcare Conference in New York, New York on Wednesday, November 12 at 3:30 p.m. Eastern Time. A copy of this press release is attached.

 

Item 7. Financial Statements and Exhibits.

 

  (c)   Exhibits

 

    Exhibit No.
   

Description

   

99.1

    Press release dated November 5, 2003.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

           

SALIX PHARMACEUTICALS, LTD.

 

Date: November 5, 2003           By:   /s/ Adam C. Derbyshire
             
               

Adam C. Derbyshire

Senior Vice President and Chief Financial Officer

 EX-99.2 3 dex992.htm PRESS RELEASE-NOVEMBER 5, 2003 Press Release-November 5, 2003

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Contact:

  

Adam C. Derbyshire

   

Mike Freeman

     
   

Senior Vice President and

   

Director, Investor Relations and

     
   

Chief Financial Officer

   

Corporate Communications

     
   

919-862-1000

   

919-862-1000

     

 

SALIX PHARMACEUTICALS TO PRESENT AT

CIBC WORLD MARKETS HEALTHCARE

CONFERENCE

 

RALEIGH, NC, November 5, 2003—Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will present at the CIBC World Markets Fourteenth Annual Healthcare Conference in New York, NY on Wednesday, November 12 at 3:30 p.m. ET.

 

Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available beginning at 6:30 p.m. ET, Wednesday, November 12, and will be available through Tuesday, November 18.

 

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s 100-member gastroenterology specialty sales and marketing team. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP.”

 

For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.

-----END PRIVACY-ENHANCED MESSAGE-----